Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma
Laurent Jallades,
Lucile Baseggio,
Pierre Sujobert,
Sarah Huet,
Kaddour Chabane,
Evelyne Callet-Bauchu,
Aurélie Verney,
Sandrine Hayette,
Jean-Pierre Desvignes,
David Salgado,
Nicolas Levy,
Christophe Béroud,
Pascale Felman,
Françoise Berger,
Jean-Pierre Magaud,
Laurent Genestier,
Gilles Salles,
Alexandra Traverse-Glehen
Affiliations
Laurent Jallades
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d’Hématologie, Pierre-Bénite, France;Cancer Research Center of Lyon, INSERM 1052 CNRS 5286, Team “Clinical and Experimental Models of Lymphomagenesis”, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Oulins, France
Lucile Baseggio
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d’Hématologie, Pierre-Bénite, France;Cancer Research Center of Lyon, INSERM 1052 CNRS 5286, Team “Clinical and Experimental Models of Lymphomagenesis”, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Oulins, France
Pierre Sujobert
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d’Hématologie, Pierre-Bénite, France;Cancer Research Center of Lyon, INSERM 1052 CNRS 5286, Team “Clinical and Experimental Models of Lymphomagenesis”, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Oulins, France;Université Claude Bernard Lyon-1, Marseillee, France
Sarah Huet
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d’Hématologie, Pierre-Bénite, France;Cancer Research Center of Lyon, INSERM 1052 CNRS 5286, Team “Clinical and Experimental Models of Lymphomagenesis”, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Oulins, France;Université Claude Bernard Lyon-1, Marseillee, France
Kaddour Chabane
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d’Hématologie, Pierre-Bénite, France;Cancer Research Center of Lyon, INSERM 1052 CNRS 5286, Team “Clinical and Experimental Models of Lymphomagenesis”, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Oulins, France
Evelyne Callet-Bauchu
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d’Hématologie, Pierre-Bénite, France;Cancer Research Center of Lyon, INSERM 1052 CNRS 5286, Team “Clinical and Experimental Models of Lymphomagenesis”, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Oulins, France;Université Claude Bernard Lyon-1, Marseillee, France
Aurélie Verney
Cancer Research Center of Lyon, INSERM 1052 CNRS 5286, Team “Clinical and Experimental Models of Lymphomagenesis”, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Oulins, France;Université Claude Bernard Lyon-1, Marseillee, France
Sandrine Hayette
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d’Hématologie, Pierre-Bénite, France;Cancer Research Center of Lyon, INSERM 1052 CNRS 5286, Team “Clinical and Experimental Models of Lymphomagenesis”, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Oulins, France
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d’Hématologie, Pierre-Bénite, France;Cancer Research Center of Lyon, INSERM 1052 CNRS 5286, Team “Clinical and Experimental Models of Lymphomagenesis”, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Oulins, France
Françoise Berger
Cancer Research Center of Lyon, INSERM 1052 CNRS 5286, Team “Clinical and Experimental Models of Lymphomagenesis”, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Oulins, France;Université Claude Bernard Lyon-1, Marseillee, France;Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d’Anatomie Pathologique, Pierre-Bénite, France
Jean-Pierre Magaud
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d’Hématologie, Pierre-Bénite, France;Cancer Research Center of Lyon, INSERM 1052 CNRS 5286, Team “Clinical and Experimental Models of Lymphomagenesis”, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Oulins, France;Université Claude Bernard Lyon-1, Marseillee, France
Laurent Genestier
Cancer Research Center of Lyon, INSERM 1052 CNRS 5286, Team “Clinical and Experimental Models of Lymphomagenesis”, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Oulins, France
Gilles Salles
Cancer Research Center of Lyon, INSERM 1052 CNRS 5286, Team “Clinical and Experimental Models of Lymphomagenesis”, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Oulins, France;Université Claude Bernard Lyon-1, Marseillee, France;Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d’Hématologie, Pierre-Bénite, France
Alexandra Traverse-Glehen
Cancer Research Center of Lyon, INSERM 1052 CNRS 5286, Team “Clinical and Experimental Models of Lymphomagenesis”, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Oulins, France;Université Claude Bernard Lyon-1, Marseillee, France;Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d’Anatomie Pathologique, Pierre-Bénite, France
Splenic diffuse red pulp lymphoma is an indolent small B-cell lymphoma recognized as a provisional entity in the World Health Organization 2008 classification. Its precise relationship to other related splenic B-cell lymphomas with frequent leukemic involvement or other lymphoproliferative disorders remains undetermined. We performed whole-exome sequencing to explore the genetic landscape of ten cases of splenic diffuse red pulp lymphoma using paired tumor and normal samples. A selection of 109 somatic mutations was then evaluated in a cohort including 42 samples of splenic diffuse red pulp lymphoma and compared to those identified in 46 samples of splenic marginal zone lymphoma and eight samples of hairy-cell leukemia. Recurrent mutations or losses in BCOR (the gene encoding the BCL6 corepressor) – frameshift (n=3), nonsense (n=2), splicing site (n=1), and copy number loss (n=4) – were identified in 10/42 samples of splenic diffuse red pulp lymphoma (24%), whereas only one frameshift mutation was identified in 46 cases of splenic marginal zone lymphoma (2%). Inversely, KLF2, TNFAIP3 and MYD88, common mutations in splenic marginal zone lymphoma, were rare (one KLF2 mutant in 42 samples; 2%) or absent (TNFAIP3 and MYD88) in splenic diffuse red pulp lymphoma. These findings define an original genetic profile of splenic diffuse red pulp lymphoma and suggest that the mechanisms of pathogenesis of this lymphoma are distinct from those of splenic marginal zone lymphoma and hairy-cell leukemia.